SynthesisInteractive cardiovascular and thoracic surgery2022
Risk factors for acute exacerbation of interstitial lung disease following lung cancer resection: a systematic review and meta-analysis.
Synthesis in Interactive cardiovascular and thoracic surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Lung cancer resection in patients with underlying usual interstitial pneumonia: a meta-analysis.BMJ open respiratory research · 2023Pooled it
- [Surgical Management of Lung Cancer in Patients with Interstitial Lung Disease].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Surgical outcomes and prognoses of patients with clinical stage I lung cancer and interstitial lung disease.General thoracic and cardiovascular surgery · 2026Article
- Care of the Patient with Interstitial Lung Disease Perioperatively.Current rheumatology reports · 2026Review
- Risk Factors for Postoperative Acute Exacerbations and Long-Term Survival in Patients with Concomitant Lung Cancer and Idiopathic Pulmonary Fibrosis.Annals of surgical oncology · 2026Article
- Mortality and factors associated with acute exacerbation after non-cardiac surgery in patients with interstitial pneumonia: a retrospective study.Korean journal of anesthesiology · 2025Article
- Concomitant Idiopathic Pulmonary Fibrosis and Lung Cancer: An Updated Narrative Review.Advances in respiratory medicine · 2025Review
- The value of fibrosis score andJournal of thoracic disease · 2025Article
- Perioperative Anti-Fibrotic Treatment Prevents Acute Exacerbation of Idiopathic Pulmonary Fibrosis After Lung Cancer Surgery.Life (Basel, Switzerland) · 2024Article
- Successful management of interstitial lung disease in dermatomyositis complicated by malignancy: a case-based review.Rheumatology international · 2024Article
- Predictors for acute exacerbation of interstitial pneumonia following lung cancer surgery: a multicenter study.BMC pulmonary medicine · 2024Article
- Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review.Frontiers in medicine · 2024Review
- Serum KL-6 levels predict the occurrence and severity of treatment-related interstitial lung disease in lung cancer.Scientific reports · 2023Article
- Article
- A nomogram for the prediction of the survival of patients with advanced non-small cell lung cancer and interstitial lung disease.Cancer medicine · 2023Article
- A predictive model for acute exacerbation of idiopathic interstitial pneumonias.The European respiratory journal · 2023Observational
- Pneumonitis in Older Patients With Non-squamous Non-small Cell Lung Cancer Treated With Pembrolizumab and Pemetrexed.In vivo (Athens, Greece)Article
- Adjuvant surgical resection for nontuberculous mycobacterial pulmonary disease: Effectiveness and complications.Annals of thoracic medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectivesThe aim of this study was to investigate the risk factors for acute exacerbation (AE) of interstitial lung disease (ILD) following lung cancer resection.
methodsWe performed a literature screening on the databases including PubMed, Embase, Ovid MEDLINE® and the Web of Science for related studies published up to January 2021. Eligible studies were included and data on risk factors related to postoperative AE were extracted. All analyses were performed with random-effect model.
resultsA total of 12 studies of 2655 lung cancer patients with ILD were included in this article. The meta-analysis indicated that male [odds ratios (ORs) = 1.78, 95% confidence interval (CI): 1.02-3.11, P = 0.041], usually interstitial pneumonia pattern on CT (OR = 1.52, 95% CI: 1.06-2.17, P = 0.021), Krebs von den Lungen-6 [standardized mean difference (SMD) = 0.50, 95% CI: 0.06-0.94, P = 0.027], white blood cell (SMD = 0.53, 95% CI: 0.12-0.93, P = 0.010), lactate dehydrogenase (SMD = 0.47, 95% CI: 0.04-0.90, P = 0.032), partial pressure of oxygen (weighted mean difference = -3.09, 95% CI: -5.99 to -0.19, P = 0.037), surgery procedure (OR = 2.31, 95% CI: 1.42-3.77, P < 0.001) and operation time (weighted mean difference = 28.26, 95% CI: 1.13-55.39, P = 0.041) were risk factors for AE of ILD following lung cancer resection.
conclusionsWe found that males, usually interstitial pneumonia pattern on CT, higher levels of Krebs von den Lungen-6, lactate dehydrogenase, white blood cell, lower partial pressure of oxygen, greater scope of operation and longer operation time were risk factors for AE of ILD following lung cancer resection. Patients with these risk factors should be more prudently selected for surgical treatment and be monitored more carefully after surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.